Biosergen
Biosergen publishes interim report for first quarter 2023
REG
Summary of the Interim Report for Q1 2023
| 2023 | 2022 | 2022 | |
| TSEK | Jan-Mar | Jan-Mar | Jan-Dec |
| Profit/loss | |||
| Other income | 5,315 | 1,317 | 5,183 |
| Profit/loss before depreciation (EBITDA | -5,029 | -5,018 | -34,129 |
| Operating profit/loss before net financials | -5,029 | -5,018 | -34,129 |
| Net financials | 2 | 3 | 81 |
| Netprofit/loss for the period | -5,027 | -5,015 | -34,048 |
| Earnings per share (SEK) | -0.18 | -0.18 | -1.09 |
Highlights during Q1 2023
- March 29, Biosergen provides Phase 2 clinical development strategy update.
- March 13, Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
- January 16, Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial.
Highlights after the period
There have been no highlighe´ts after the period
The Financial report can be found on our website: https://biosergen.net/investors/filings
| Datum | 2023-05-31, kl 19:05 |
| Källa | Cision |
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.